Avelos Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $12.4M

  • Investors
  • 17

Avelos Therapeutics General Information

Description

Developer of precision oncology therapeutics designed to target synthetic lethality and DNA damage response pathways in cancer cells. The company focuses on discovering and developing small-molecule drug candidates that target master regulators of the DNA damage response and cell division cycles, utilizes genomics-driven target discovery and structural biology platforms to evaluate tumor vulnerabilities; and conducts preclinical characterization and translational research across multiple oncological indications, enabling oncologists and clinical researchers to advance targeted anticancer therapies that overcome drug resistance and improve patient survival outcomes.

Contact Information

Website
www.avelostx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 21 Magokjungang 8-ro 7-gil
  • Room Number 325, Gangseo-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 21 Magokjungang 8-ro 7-gil
  • Room Number 325, Gangseo-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Avelos Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 02-May-2024 $12.4M Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 18-Jul-2022 Completed Pre-Clinical Trials
2. Accelerator/Incubator 30-May-2022 Completed Pre-Clinical Trials
1. Seed Round 30-Apr-2022 Completed Startup
To view Avelos Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Avelos Therapeutics Patents

  • 36

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 28

    Pending

  • Expiring in next 12 mo

Avelos Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026104998-A1 Substituted imidazopyridine compound derivatives and their pharmaceutical use Pending 14-Nov-2024
WO-2026078495-A1 Seleno-fused heteroring compound derivatives and their pharmaceutical use Pending 11-Oct-2024
WO-2026058156-A1 Sulfur or selenium-containing compound derivatives and their pharmaceutical use Pending 12-Sep-2024
WO-2026047509-A1 Substituted triazine compound derivatives and their pharmaceutical use Pending 26-Aug-2024
AU-2025319839-A1 Substituted aryl or heteroaryl compound derivatives and pharmaceutical use thereof Pending 09-Aug-2024
To view Avelos Therapeutics’s complete patent history, request access »

Avelos Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avelos Therapeutics Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Heungkuk Securities Corporation Minority
LSK Investment Venture Capital Minority
Shinhan Capital Venture Capital Minority
Starset Investment Venture Capital Minority
Medytox Venture Investment Corporate Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial

Avelos Therapeutics FAQs

  • When was Avelos Therapeutics founded?

    Avelos Therapeutics was founded in 2021.

  • Where is Avelos Therapeutics headquartered?

    Avelos Therapeutics is headquartered in Seoul, South Korea.

  • What is the size of Avelos Therapeutics?

    Avelos Therapeutics has 21 total employees.

  • What industry is Avelos Therapeutics in?

    Avelos Therapeutics’s primary industry is Drug Discovery.

  • Is Avelos Therapeutics a private or public company?

    Avelos Therapeutics is a Private company.

  • What is Avelos Therapeutics’s current revenue?

    The current revenue for Avelos Therapeutics is .

  • How much funding has Avelos Therapeutics raised over time?

    Avelos Therapeutics has raised $21.6M.

  • Who are Avelos Therapeutics’s investors?

    Heungkuk Securities, LSK Investment, Shinhan Capital, Starset Investment, and Medytox Venture Investment are 5 of 17 investors who have invested in Avelos Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process